Clinical Trial: Cohort Study of Osimertinib Combined with Pemetrexed and Carboplatin as First-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients with Poor Prognosis EGFR Mutations (China)

Posted On: 2026-08-12

China, Aug. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Cohort Study of Osimertinib Combined with Pemetrexed and Carboplatin as First-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients with Poor Prognosis EGFR Mutations'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129932

Registration Time: 2026/08/12

Type: Observational study

Primary Sponsor: Peking University First Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=292083

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Cohort Study of Osimertinib Combined with Pemetrexed and Carboplatin as First-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients with Poor Prognosis EGFR Mutations (China)